REGENXBIO Inc. RGNX
$8.91
+10.61%
at last close
Analyst Consensus
- Consensus Rating
- Buy (8 Buy · 2 Hold · 0 Sell)
- Average Price Target
- $23.70
- Implied Upside
- +166.0%
- Price Target Range
- $12.00 – $50.00
- Analysts (12 mo)
- 10
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-25 | HC Wainwright & Co.Yi Chen |
Maintains | Buy | $23 → $21 |
| 2026-08-25 | BairdBrian Skorney |
Maintains | Outperform | $32 → $29 |
| 2026-08-10 | HC Wainwright & Co.Yi Chen |
Maintains | Buy | $26 → $23 |
| 2026-08-07 | BarclaysEliana Merle |
Downgrades | Overweight → Equal-weight | $12 |
| 2026-06-24 | HC Wainwright & Co.Yi Chen |
Reiterates | Buy | $26 |
| 2026-06-22 | BairdBrian Skorney |
Maintains | Outperform | $27 → $32 |
| 2026-06-22 | Leerink PartnersMani Foroohar |
Maintains | Outperform | $17 → $18 |
| 2026-06-05 | HC Wainwright & Co.Yi Chen |
Maintains | Buy | $30 → $26 |
| 2026-05-15 | B of A SecuritiesGeoff Meacham |
Maintains | Buy | $25 → $14 |
| 2026-05-15 | BarclaysGena Wang |
Maintains | Overweight | $37 → $12 |
| 2026-03-09 | HC Wainwright & Co.Yi Chen |
Maintains | Buy | $32 → $30 |
| 2026-03-06 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $18 → $17 |
| 2026-02-10 | HC Wainwright & Co.Yi Chen |
Maintains | Buy | $34 → $32 |
| 2026-02-10 | Goldman SachsPaul Choi |
Maintains | Neutral | $14 → $12 |
| 2026-02-10 | Morgan StanleyJudah Frommer |
Maintains | Overweight | $25 → $18 |
| 2026-02-10 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 → $50 |
| 2026-01-29 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 |
| 2025-12-19 | StifelAnnabel Samimy |
Maintains | Buy | $40 → $45 |
| 2025-12-15 | Leerink PartnersMani Foroohar |
Maintains | Outperform | $16 → $20 |
| 2025-11-20 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 |
| 2025-11-07 | RBC CapitalLuca Issi |
Maintains | Outperform | $17 → $19 |
| 2025-10-07 | HC Wainwright & Co.Yi Chen |
Reiterates | Buy | $34 |
| 2025-09-08 | HC Wainwright & Co.Yi Chen |
Reiterates | Buy | $34 |
| 2025-09-08 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 |
| 2025-08-19 | HC Wainwright & Co.Yi Chen |
Reiterates | Buy | $34 |
| 2025-08-08 | RBC CapitalLuca Issi |
Maintains | Outperform | $21 → $17 |
| 2025-08-08 | BarclaysGena Wang |
Maintains | Overweight | $50 → $37 |
| 2025-08-08 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 |
| 2025-06-09 | Chardan CapitalDaniil Gataulin |
Maintains | Buy | $52 |
| 2025-04-17 | Goldman SachsPaul Choi |
Maintains | Neutral | $14 → $12 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $8.91
- Market Cap
- $531.74 million
- 52-Week Range
- $5.46 – $16.19
- Average Volume
- 1.58 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.